# VK2735 Phase 2 VENTURE Trial: 14.7% Weight Loss in 13 Weeks | This GLP

In the 13-week VENTURE phase 2 trial, weight fell 9.1% to 14.7% on VK2735 against 1.7% on placebo, and 93% of treated participants lost at least 5% | why a 13-week figure is not a 68-week one.

Publisher: This GLP Editorial Team
Canonical: https://thisglp.com/research/ninety-three-percent-in-thirteen-weeks
Updated: 2026-09-18
Published: 2026-09-17

[← Research](https://thisglp.com/research)

Evidence

# VK2735 Phase 2 VENTURE Trial: 14.7% Weight Loss in 13 Weeks

The GIP and GLP-1 dual agonist VK2735 took off up to 14.7% of body weight in a 13-week phase 2 trial. The approved drugs report figures from trials of 68 weeks or longer.

[This GLP Editorial Team](https://thisglp.com/about)September 20265 min readUpdated September 2026

Weight change at week 13 — not week 68 · 15 mg · −14.7% · 2.5 mg · −9.1% · placebo · −1.7% · 93% of treated participants lost at least 5%. · 174 people, one quarter of a year, phase 2.

**Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms).

## Key takeaways

-   VENTURE was a 13-week phase 2 dose-ranging trial of weekly injected VK2735, another GIP and GLP-1 dual agonist, in adults with obesity or overweight and at least one comorbidity.
-   Weight fell 9.2 kg (9.1%) at 2.5 mg and 14.6 kg (14.7%) at 15 mg, against 1.8 kg (1.7%) on placebo.
-   At least 5% of body weight was lost by 93% of treated participants (130 of 140) against 12% on placebo (4 of 34).
-   Gastrointestinal events were the common adverse events and became less frequent after titration reached steady state.

Read the timeline before the numbers. This trial ran 13 weeks [\[1\]](https://thisglp.com/research/ninety-three-percent-in-thirteen-weeks#ref-1). Every approved drug figure on this site — the ones in [the pooled weight-loss averages](https://thisglp.com/research/glp1-weight-loss-pooled-average) — comes from trials of 68 weeks or longer. A 14.7% result at three months and a 15% result at sixteen months are not the same claim, and setting them side by side is the single easiest way to mislead a reader about a pipeline drug.

With that established, the numbers are striking. Weight fell 9.2 kg at the 2.5 mg dose and 14.6 kg at 15 mg, against 1.8 kg on placebo. In proportional terms that is 9.1% and 14.7% against 1.7%. Losing at least 5% of body weight was achieved by 130 of 140 treated participants — 93% — against 4 of 34 on placebo.

A 93% response rate in 174 people is a phase 2 finding

Dose-ranging trials are designed to find which doses do something, not to establish how much. The arms here are small, the population excluded anyone with diabetes, and a quarter of a year is short enough that the weight curve on every drug in this class is still steep. What VENTURE establishes is that all tested doses work; what it cannot establish is where any of them land.

VK2735 pairs GLP-1 with GIP, the same combination as tirzepatide, which makes it a competitor rather than a new mechanism. That distinguishes it from the glucagon pairing this site covered in [the survodutide phase 3 result](https://thisglp.com/research/survodutide-synchronize-1) and from the amylin pairing in CagriSema. The pipeline is now several molecules deep on each of three mechanisms.

On tolerability, the adverse events were predominantly gastrointestinal and their reported frequency fell once titration reached steady state. That pattern — worst during escalation, better after — recurs across this class and is the reason dose ladders exist, as this site set out in [what titration does to the nausea](https://thisglp.com/research/how-long-does-nausea-last-on-a-glp1).

None of this is purchasable. VK2735 completed a phase 2 study and has no approval anywhere. The reason to record it is that the pipeline determines what the market looks like in three years, and a drug that clears phase 2 cleanly is the kind that eventually changes what the approved options cost — the pipeline this site tracks in [what is not for sale](https://thisglp.com/research/what-new-weight-loss-drugs-are-coming).

## Frequently asked

Is 14.7% comparable to what semaglutide or tirzepatide achieve?

No. This trial ran 13 weeks; the approved-drug figures come from trials of 68 weeks or more. The curves are still steep at three months in every drug in this class.

How many people were in the trial?

174 — 140 across the active dose arms and 34 on placebo. It was a phase 2 dose-ranging study, and people with diabetes were not eligible.

Can I buy VK2735?

No. It has completed a phase 2 study and is not approved or sold anywhere.

## Sources

1.  \[1\] Bays HE, Toth P, Alkhouri N, Pullman J, Freilich B, Neutel J (2026). Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study Obesity. [PMID 41508550](https://pubmed.ncbi.nlm.nih.gov/41508550/)

## Where to get it

### Best GLP-1 injections

Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured.

[Compare providers →](https://thisglp.com/best/compounded-semaglutide)

## More in Evidence

-   [
    
    150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability
    
    ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms
    
    ](https://thisglp.com/research/exercise-on-ozempic)
-   [
    
    STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower.
    
    ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show
    
    ](https://thisglp.com/research/does-ozempic-lower-cholesterol)
-   [
    
    Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight.
    
    ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found
    
    ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)